These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 4110180)

  • 21. [Pharmacology of a heparinoid derived from pentosan].
    Lansen J; Diner H
    Agressologie; 1983 Dec; 24(12):591-5. PubMed ID: 6199994
    [No Abstract]   [Full Text] [Related]  

  • 22. [Action of an extractive heparinoid on some blood coagulation indices].
    Guidi G; Lombardi V; Torsellini A
    Minerva Med; 1969 Dec; 60(99 Suppl):5034-8. PubMed ID: 4188587
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of various doses of SP 54 on fibrinolytic activity in patients with thrombotic diseases.
    Losonczy H; Nagy I; Dávid M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(3):388-93. PubMed ID: 2465236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacological aspects of the fibrinolytic activity of Ateroid].
    Prino G; Mantovani M
    Minerva Med; 1969 Dec; 60(99 Suppl):5015-22. PubMed ID: 4188585
    [No Abstract]   [Full Text] [Related]  

  • 25. Clotting and fibrinolysis.
    Prentice CR
    J Clin Pathol Suppl (R Coll Pathol); 1975; 9():50-3. PubMed ID: 182726
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical studies on the fibrinolytic action of pentosan polysulfate].
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):272-7. PubMed ID: 2427410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Shifts in coagulating and fibrinolytic activity of the blood following the administration of nerobol in patients with coronary atherosclerosis].
    Kratovskaia OV; Zalaldinova NB; Afaunova VI; Denisova TP; Lebedeva SN
    Ter Arkh; 1972 Sep; 44(9):29-31. PubMed ID: 4660396
    [No Abstract]   [Full Text] [Related]  

  • 28. [Use of the thromboelastograph for registration of the time of euglobulin lysis in normal rats and those with experimentally modified fibrinolysis].
    Prino G; Mantovani M; Butti A
    Farmaco Prat; 1969 Sep; 24(9):552-61. PubMed ID: 4187112
    [No Abstract]   [Full Text] [Related]  

  • 29. [Influence polyunsaturated fatty acids omega-3 on coagulation and fibrinolysis systems in patients with NIDDM].
    Panchenko VM; Karabasova MA; Liutova LV; Togoev AM; Ershov AA; Chernova GI; Isaev VA
    Klin Med (Mosk); 2002; 80(2):40-3. PubMed ID: 11898721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative analysis of the influence of heparin, HCG and SP 54 on NEFA and free glycerol in arteriosclerosis].
    Notarbartolo A; Di Sciacca A; Campisi D
    Boll Soc Ital Cardiol; 1971; 16(2):77-82. PubMed ID: 5138235
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pathogenesis of atherosclerosis. Fibrinolytic and purifying therapy].
    Noel B
    Phlebologie; 1967; 20(3):329-33. PubMed ID: 4168154
    [No Abstract]   [Full Text] [Related]  

  • 32. [Current state of anticoagulant and fibrinolytic therapy].
    Hladovec J
    Cas Lek Cesk; 1971 Oct; 110(42):969-75. PubMed ID: 5114558
    [No Abstract]   [Full Text] [Related]  

  • 33. [Laboratory investigations on the effect of a heparinoid].
    Harmanci N; Akman N; Ulutin ON
    Rev Med Moyen Orient; 1965; 22(6):541-5. PubMed ID: 5217700
    [No Abstract]   [Full Text] [Related]  

  • 34. [On the fibrinolytic effect of heparin and heparinoids].
    Naegeli T; Matis P
    Zentralbl Chir; 1965 Jun; 90(23):881-3. PubMed ID: 4157844
    [No Abstract]   [Full Text] [Related]  

  • 35. Action on fibrinolysis and platelet aggregation of a synthetic, heparin-like sulfated polyanion (SP 54) given orally and parenterally, as related to lipidic fractions. Trials on long-term prophylactic treatment under double-blind conditions.
    Frandoli G; Spreafico PL; Lampugnani P; Tammaro AE
    Arzneimittelforschung; 1972 Apr; 22(4):759-63. PubMed ID: 4340341
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effect of cytochrome C, sulnate and contrical on a change in the blood coagulating system and fibrinolysis during blood flow recovery in ischemic extremities].
    Levandovskiĭ IV; Shal'nev AN
    Patol Fiziol Eksp Ter; 1979; (6):26-9. PubMed ID: 94430
    [No Abstract]   [Full Text] [Related]  

  • 37. [Evaluation of hematic fibrinolytic activity in patients treated with an extractive mucopolysaccharide complex].
    Spampinato N
    Minerva Med; 1969 Dec; 60(99 Suppl):5068-76. PubMed ID: 4188591
    [No Abstract]   [Full Text] [Related]  

  • 38. [On the physiology of blood coagulation and fibrinolysis as the basic principles in the clinical use of anticoagulants, thrombolytics and inhibitors of fibrinolysis].
    Van de Loo J
    Rev Colomb Obstet Ginecol; 1967; 18(5):321-6. PubMed ID: 5612568
    [No Abstract]   [Full Text] [Related]  

  • 39. The fibrinolytic system in arteriosclerosis.
    O'Brien ET
    J Ir Med Assoc; 1969 Jun; 62(384):203-12. PubMed ID: 4892241
    [No Abstract]   [Full Text] [Related]  

  • 40. [Hyperlipemia and hypofibrinolysis in arteriosclerotic disease].
    Prino G; Mantovani M
    Boll Chim Farm; 1967 Feb; 106(2):67-84. PubMed ID: 4893083
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.